Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 3,574 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: T cells Clear all

Conditions: Hematologic Malignancies
Interventions: Granulocyte Colony Stimulating Factor; Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 22 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: darbepoetin alfa, epoetin alfa; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma
Interventions: NX-1607, Paclitaxel; Drug
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 10
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 7 more

Conditions: Esophageal Cancer, Lung Cancer, Lymphoma
Interventions: topotecan hydrochloride, low-LET electron therapy, low-LET photon therapy; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2000
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: T Cell Malignancies
Interventions: ELA026; Drug
Lead sponsor: Electra Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: New Haven, Connecticut • Atlanta, Georgia • Grand Rapids, Michigan + 3 more

Conditions: Asthma
Interventions: Segmental airway allergen challenge, Bronchoscopy, Methacholine challenge test, Spirometry, Allergen skin prick test; Biological · Procedure · Diagnostic Test
Lead sponsor: Prescott Woodruff; Other
Eligibility: 18 Years to 50 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Relapse Remitting Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chimeric Antigen Receptor T-cell Therapy, Hematologic Malignancy
Interventions: WAYPOINT; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lymphoma, Leukemia, Myeloproliferative Disorders, Multiple Myleoma, Myelodysplastic Syndrome
Interventions: Rituximab, Fludarabine, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Peripheral blood stem cell (PBSC) transplantation, T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells, Prednisone, Allogeneic hematopoietic stem cell transplant (HSCT), Filgrastim, T-Rapa cell Donor Lymphocyte Infusion (DLI); Drug · Procedure · Genetic
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 11 Years to 90 Years
Enrollment: 442 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2017
U.S. locations: 2
States / cities: Bethesda, Maryland • Hackensack, New Jersey

Conditions: T-cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma
Interventions: Decitabine, Venetoclax, Calaspargase pegol-mknl; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 1 Month to 21 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: B-ALL, B-cell Non Hodgkin Lymphoma, DLBCL, Follicular Lymphoma Grade 3B
Interventions: Fludarabine, Cyclophosphamide, CD22 CAR; Drug
Lead sponsor: Matthew Frank; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hodgkin's Disease, Non Hodgkin's Lymphoma, Myeloma, Leukemia, Myelodysplasia
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Metastatic Colorectal Cancer
Interventions: Botensilimab, Balstilimab, Standard of Care; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 26
States / cities: Scottsdale, Arizona • Duarte, California • Los Angeles, California + 18 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Thrombocytopenia
Interventions: filgrastim, vitamin E, busulfan, cytarabine, etoposide, fludarabine phosphate, isotretinoin, topotecan hydrochloride, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation; Biological · Dietary Supplement · Drug + 1 more
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 19 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), PTCL-NOS, ALCL, AITL
Interventions: AZD3470, Pembrolizumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 7
States / cities: Duarte, California • Miami, Florida • Atlanta, Georgia + 4 more

Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions: Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate, Rituximab; Biological · Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Malignant Diseases, Non-malignant Diseases
Interventions: CliniMACS CD34+ cell enrichment and T-cell depletion; Device
Lead sponsor: Rajni Agarwal; Other
Eligibility: Up to 35 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Multiple Myeloma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Multiple Myeloma
Interventions: Biospecimen Collection, Cognitive Intervention, Electronic Health Record Review, Survey Administration; Procedure · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, B-cell Marginal Zone, Waldenstrom Macroglobulinemia, Lymphoma, Mantle Cell
Interventions: LY4152199 - IV; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 23
States / cities: Duarte, California • Aurora, Colorado • Denver, Colorado + 17 more

Conditions: Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Burkitt Lymphoma
Interventions: Pirtobrutinib, LV20.19 CAR T cells; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 81 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Urothelial Carcinoma, Head and Neck Cancer, Melanoma, Bladder Urothelial Carcinoma
Interventions: Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells; Genetic
Lead sponsor: Adaptimmune; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: Boston, Massachusetts • St Louis, Missouri • Buffalo, New York + 4 more

Conditions: Triple-Negative Breast Cancer (TNBC)
Interventions: BreakVax, Ipilimumab 2.5 mg, Pembrolizumab, Standard-of-care chemotherapy, Losartan and aspirin; Drug
Lead sponsor: BreakBio Corp; Industry
Eligibility: 18 Years to 72 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Lymphocytic Leukemia in Relapse, Small Lymphocytic Lymphoma, Relapsed, Waldenstrom's Macroglobulinemia Recurrent, Follicular B-cell Non-Hodgkin's Lymphoma, B-cell Lymphoma Refractory, Mantle Cell Lymphoma Recurrent, Hairy Cell Leukemia, Diffuse Large B Cell Lymphoma, Waldenstrom's Macroglobulinemia Refractory, Mantle Cell Lymphoma Refractory
Interventions: Prior MB-102 CAR-T cell investigational product., Prior MB-106 CAR-T cell investigational product.; Biological
Lead sponsor: Mustang Bio; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Orange, California • Boston, Massachusetts • Rochester, New York + 2 more

Conditions: Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
Interventions: Ipilimumab, Osimertinib; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome

Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer

A Study of NX-1607 in Adults With Advanced Malignancies

Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma

A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

Study of the Inflammation and Airway Changes That Occur After Exposure to Allergen in Asthmatics

Deficient T Regulatory Cell (Treg) Function in Patients With Relapsing Remitting Multiple Sclerosis

Symptom Monitoring and Management Intervention After CAR-T

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

CD34+ Cell Enriched and T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Mismatched Related Donors or Borderline Organ Function

A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC